Treatment of previously untreated follicular lymphoma with atezolizumab combined with obinutuzumab and bendamustine was associated with widespread adverse events and a treatment-related death, according to an interim analysis of a phase Ib/II cohort study.
The FDA has expanded the approval of the PARP inhibitor olaparib (Lynparza) to include the treatment of patients with metastatic breast cancer who have a mutated BRCA gene.
After undergoing treatment, women with young-onset breast cancer and BRCA mutations had similar survival rates as those women who were not mutation carriers, according to the results of a prospective study.
The EGFR tyrosine kinase inhibitor osimertinib showed promising efficacy and manageable toxicity in patients with advanced NSCLC and CNS metastases.
Nearly two-thirds of older patients with stage III lung cancer do not receive any treatment, according to a new study.
Reduced expression of PBRM1 and VHL was correlated with increased tumor aggressiveness in clear cell renal cell carcinoma, according to the results of a recent study.
Duvelisib improved the median progression-free survival of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma by about 3.5 months compared with the current standard, ofatumumab.
Only a small percentage of patients undergoing active surveillance for papillary thyroid carcinoma will experience increases in tumor diameter by 3 mm or more during the first 5 years of surveillance.
Lenalidomide plus rituximab failed to demonstrate superiority over standard of care for follicular lymphoma in the phase III RELEVANCE trial.
Metastatic melanoma patients treated with pembrolizumab who achieve a complete response can maintain those responses, even after discontinuation of therapy.